About Aegle Therapeutics
Aegle Therapeutics is a private company based in Woburn, Massachusetts. It has reported $9,233,393 raised in three offerings on Form D since January 2020. Its chief executive is Shelley Hartman.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 4, 2026 | Aug 28, 2026 | $2,277,698fully sold | 17 | $133K | EquityRule 506(b) | Form D ↗ |
| Dec 30, 2025 | Mar 3, 2026 | $455,695of $700K target | 10 | $45,570 | DebtRule 506(b) | Form D ↗ |
| Jan 3, 2020 | Jan 7, 2020amended Jul 28, 2020 | $6,500,000fully sold | 8 | $812K | EquityRule 506(b) | Form D/A ↗2 earlier filings |
| Total, three offerings | $9,233,393 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Aegle Therapeutics's Form D filed Aug 28, 2026.
Earlier filings also listed Steve O'Hara (director, last listed Mar 2026), Mikio Tanji (director, last listed Mar 2026), David Schimel (director, last listed Mar 2026), Robert Williamson, Jr. (executive officer and director, last listed Jul 2020), Robert Ryan (director, last listed Jul 2020) and Elona Baum (director, last listed Jul 2020).